DAN L. LONGO, M.D.; ROBERT C. YOUNG, M.D.; SUSAN M. HUBBARD, R.N.; MARGARET WESLEY, Ph.D.; RICHARD I. FISHER, M.D.; ELAINE JAFFE, M.D.; COSTAN BERARD, M.D.; VINCENT T. DeVITA Jr., M.D.
Seventy-nine patients with nodular mixed lymphoma were treated at the National Cancer Institute between 1966 and 1978. Fifteen patients had stage I or II disease, and 64, stage III or IV disease. The overall complete response rate for the patients that received various primary treatment regimens was 76%, with 52% of complete responders remaining in their first remission at a median follow-up of 7 years. Median survival of complete responders is projected to be more than 13 years. Median survival of patients who do not achieve complete remission is less than 2 years. Patients with B symptoms, bone marrow involvement, or a lactate dehydrogenase level greater than 250 U/mL had significantly shorter survivals than did patients without these features. Patients with advanced-stage (III and IV) nodular mixed lymphoma had a 72% complete response rate, with the average remission lasting more than 6 years. Although relapses have been seen up to 8 years after diagnosis in patients with nodular mixed lymphoma given C-MOPP chemotherapy (cyclophosphamide, vincristine, procarbazine, prednisone), prolonged initial remissions can be achieved with this therapy.
DAN L. LONGO, ROBERT C. YOUNG, SUSAN M. HUBBARD, MARGARET WESLEY, RICHARD I. FISHER, ELAINE JAFFE, et al. Prolonged Initial Remission in Patients with Nodular Mixed Lymphoma. Ann Intern Med. 1984;100:651–656. doi: 10.7326/0003-4819-100-5-651
Download citation file:
Published: Ann Intern Med. 1984;100(5):651-656.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use